Cecilie Utke Rank

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7457722/publications.pdf

Version: 2024-02-01

1307594 996975 19 227 7 15 citations g-index h-index papers 19 19 19 341 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Endothelial dysfunction and thromboembolism in children, adolescents, and young adults with acute lymphoblastic leukemia. Leukemia, 2022, 36, 361-369.	7.2	4
2	Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study. Blood Advances, 2022, 6, 138-147.	5.2	11
3	Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia. Haematologica, 2021, 106, 2824-2833.	3.5	15
4	Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study. Cancer Chemotherapy and Pharmacology, 2021, 88, 911-917.	2.3	5
5	SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 725-733.	0.4	11
6	Prevalence of nonâ€adherence and nonâ€compliance during maintenance therapy in adults with acute lymphoblastic leukemia and their associations with survival. European Journal of Haematology, 2021, ,	2.2	5
7	Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study. Leukemia and Lymphoma, 2021, , 1-10.	1.3	1
8	Pulmonary embolism in acute lymphoblastic leukemia $\hat{a} \in$ "An observational study of 1685 patients treated according to the NOPHO ALL2008 protocol. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 866-871.	2.3	6
9	Polygenic risk score-analysis of thromboembolism in patients with acute lymphoblastic leukemia. Thrombosis Research, 2020, 196, 15-20.	1.7	3
10	Management of Asparaginase Toxicity in AYAs with ALL. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S12-S13.	0.4	1
11	Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020. Seminars in Hematology, 2020, 57, 102-114.	3.4	6
12	<i>The Association between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in the NOPHO ALL2008 Protocol</i>	1.4	О
13	Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. The Cochrane Library, 2019, , .	2.8	2
14	Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia – A NOPHO ALL2008 study. Thrombosis Research, 2019, 184, 92-98.	1.7	20
15	Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood, 2018, 131, 2475-2484.	1.4	83
16	Should immunologic strategies be incorporated into frontline ALL therapy?. Best Practice and Research in Clinical Haematology, 2018, 31, 367-372.	1.7	2
17	Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leukemia and Lymphoma, 2016, 57, 348-354.	1.3	40
18	Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the <i><scp>ADAMTS</scp>13</i> gene. European Journal of Haematology, 2014, 92, 168-171.	2.2	10

#	Article	IF	CITATIONS
19	Cerebral sinovenous thrombosis and asparaginase reâ€exposure in patients aged 1–45 years with acute lymphoblastic leukaemia: A NOPHO ALL2008 study. EJHaem, 0, , .	1.0	2